ESTRO 2024 - Abstract Book

S116 ESTRO 2024 In addition, novel concepts for dose painting and response adaptive radiotherapy aiming to adapt for temporally changing individual radiation resistance patterns in the presence of various uncertainties will be introduced and discussed. Invited Speaker

3513

The "poor responder" after radiotherapy for SCCHN from radiobiological point of view

Ingeborg Tinhofer-Keilholz

Charite University Hospital Berlin, Department of Radiooncology and Radiotherapy, Berlin, Germany

Abstract:

Despite advancements in radiotherapy techniques, a subset of patients with Squamous Cell Carcinoma of the Head and Neck (SCCHN) exhibit suboptimal response to treatment. Understanding the radiobiological intricacies underlying this phenomenon is crucial for refining therapeutic strategies and improving patient outcomes. This talk delves into the complexities of radiotherapy-induced responses in SCCHN, exploring the interplay between tumor microenvironment, genetic factors, and cellular pathways. Beside summarizing previously described mechanisms involved in radioresistance, potential biomarkers and therapeutic targets to personalize treatment and mitigate resistance in SCCHN patients undergoing radiotherapy will be discussed.

3514

The elderly patient unfit for cisplatin: Then what?

Alexander Rühle

University Medical Center Leipzig, Department of Radiation Oncology, Leipzig, Germany. University Medical Center Freiburg, Department of Radiation Oncology, Freiburg, Germany

Abstract:

This presentation should present an comprehensive overview of the challenges associated with cisplatin ineligibility in elderly patients with head and neck squamous cell carcinoma (HNSCC). It delves into the prevalence of cisplatin ineligibility and explores the criteria used to determine such ineligibility. The presentation aims to highlight the global heterogeneity in the patterns of care for cisplatin-ineligible elderly HNSCC patients, juxtaposing this against international guideline recommendations. Furthermore, it discusses selected clinical trials involving cisplatin ineligible patients, such as the DHANUSH trial investigating the value of concomitant docetaxel simultaneously to radiotherapy. The current evidence regarding the use of cetuximab in the elderly population should also be discussed. Additionally, multicenter cohort analyses and selected single-center data regarding special chemotherapy regimens, e.g. carboplatin with paclitaxel, are presented. Lastly, it offers insights into future developments and ongoing clinical trials, including those concerning xevinapant. This abstract serves as a comprehensive overview of the current state, challenges, and future directions in managing cisplatin ineligibility in elderly HNSCC patients.